RU2022119586A - SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS - Google Patents

SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS Download PDF

Info

Publication number
RU2022119586A
RU2022119586A RU2022119586A RU2022119586A RU2022119586A RU 2022119586 A RU2022119586 A RU 2022119586A RU 2022119586 A RU2022119586 A RU 2022119586A RU 2022119586 A RU2022119586 A RU 2022119586A RU 2022119586 A RU2022119586 A RU 2022119586A
Authority
RU
Russia
Prior art keywords
pharmaceutically acceptable
kinase inhibitors
pyrimidine compounds
substituted pyrazolo
trk kinase
Prior art date
Application number
RU2022119586A
Other languages
Russian (ru)
Inventor
Юлия ХААС
Стивен У. ЭНДРЮС
Юйтун Цзян
Гань ЧЖАН
Original Assignee
Эррэй Биофарма Инк.
Filing date
Publication date
Application filed by Эррэй Биофарма Инк. filed Critical Эррэй Биофарма Инк.
Publication of RU2022119586A publication Critical patent/RU2022119586A/en

Links

Claims (7)

1. Соединение формулы1. Compound formula (S)-N-(5-((R)-2-(2,5-дифторфенил)пирролидин-1-ил)пиразоло[1,5-а]пиримидин-3-ил)-3-гидроксипирролидин-1-карбоксамид сульфат.(S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1- carboxamide sulfate. 2. Фармацевтическая композиция, содержащая соединение по п.1, и фармацевтически приемлемый разбавитель или носитель.2. A pharmaceutical composition containing a compound according to claim 1 and a pharmaceutically acceptable diluent or carrier. 3. Фармацевтическая композиция, проявляющая ингибирование ТРК киназы, содержащая соединение формулы I по п. 1, или его фармацевтически приемлемую соль, и фармацевтически приемлемый разбавитель или носитель.3. A pharmaceutical composition exhibiting TPK kinase inhibition, comprising a compound of formula I according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier. 4. Способ лечения рака, опосредствованного ТРК киназами, включающий введение пациенту, нуждающемуся в этом, фармацевтической композиции по п. 2.4. A method of treating cancer mediated by TRK kinases, comprising administering to a patient in need thereof a pharmaceutical composition according to claim 2. 5. Соединение по п. 1 или его фармацевтически приемлемая соль для применения в лечении рака, опосредствованного ТРК киназами.5. A compound according to claim 1 or a pharmaceutically acceptable salt thereof for use in the treatment of cancer mediated by TRK kinases.
RU2022119586A 2022-07-18 SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS RU2022119586A (en)

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2018131134A Division RU2018131134A (en) 2008-10-22 2018-08-29 SUBSTITUTED PYRAZOLO [1,5-a] PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS

Publications (1)

Publication Number Publication Date
RU2022119586A true RU2022119586A (en) 2024-01-18

Family

ID=

Similar Documents

Publication Publication Date Title
US20200325130A1 (en) Proteolysis Targeting Chimera Compounds and Methods of Preparing and Using Same
NZ592809A (en) SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS
ZA201808534B (en) Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-y l)-3-hydroxypyrrolidine-1-carboxamide
CR20220230A (en) Small molecule inhibitors of kras g12c mutant
RU2350605C2 (en) Analogues of quinazoline as inhibitors of receptor tyrosine kinases
WO2021055728A8 (en) Small molecule inhibitors of kras g12c mutant
RU2526201C2 (en) Method of treating arthritis
NZ598086A (en) Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
RU2007134380A (en) ANTIBACTERIAL PIPERIDINE DERIVATIVES
CA2443950A1 (en) Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
RU98105512A (en) APPLICATION OF PYRIMIDINE DERIVATIVES FOR CANCER PREVENTION SEPARATELY OR IN COMBINATION WITH OTHER THERAPEUTIC EVENTS
RU2014152790A (en) Pyrrolopyrazone Inhibitors of Tankyrase
RU2007124492A (en) COMBINATIONS, INCLUDING EPOTHYLONS AND PROTEINTHYROZINKINASE INHIBITORS, AND THEIR PHARMACEUTICAL USE
RU2012147511A (en) USE OF C-SRC INHIBITORS IN COMBINATION WITH PYRIMIDILAMINOBENZAMIDE FOR TREATMENT OF LEUKOSIS
AU2016252860A1 (en) Compositions and methods for inhibiting kinases
US20110281902A1 (en) Combinations comprising a protein kinase inhibitor being a pyrimidylaminobenzamide compound and a hsp90 inhibitor such as 17-aag
NZ527764A (en) Combination comprising a signal transduction inhibitor and an epothilone derivative
AU2002308218A1 (en) Combination comprising a signal transduction inhibitor and an epothilone derivative
RU2009101920A (en) 4-AMINO-3-ARILAMINO-6-ARILPYRAZOLO [3,4-d] PYRIMIDINE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND THEIR APPLICATION AS ANTIVIRAL AGENTS
RU2022119586A (en) SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS
ES2400375T3 (en) Combination comprising A) a pyrimidylaminobenzamide compound and B) a THR315LLE kinase inhibitor
RU2004110042A (en) THIENO [2,3-D] Pyrimidines with Combined Agonistic Activity LH and FSH
RU2007119776A (en) NEW AMINOPYRIDINE DERIVATIVES WITH SELECTIVE AURORA A INHIBITING ACTIVITY
JP2009511450A (en) Combination of nilotinib and farnesyltransferase inhibitor
EA200300048A1 (en) ENANTIOMER OF 1,2-ANNELIED HINAZOLINE INHIBITING PHARNESILTRANSFERASE